• Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Lexeo Therapeutics Inc.

Headquarters: New York , NY, United States
Website: https://www.lexeotx.com/
Year Founded: 2017
Status: Public
Industry Sector: HealthTechnology
CEO: R. Nolan Townsend, MBA
Number Of Employees: 72
Enterprise Value: $97,567,691
PE Ratio: -0.85
Exchange/Ticker 1: NASDAQ:LXEO
Exchange/Ticker 2: N/A
Latest Market Cap: $87,308,096

BioCentury | May 9, 2025
Management Tracks

Spark veteran Ciulla now CEO of gene therapy play Ikarovec  

Plus: eGenesis names Jay Barth CMO and updates from Cytodyn, Sera, Context, Kelso
Read More
BioCentury | Apr 16, 2025
Management Tracks

More C-suite changes at Dyne

Plus updates from Airna, Madrigal, Protara, Prologue, Alkermes and BioInnovation Institute
Read More
BioCentury | Apr 9, 2025
Product Development

Cartesian's autoimmune CAR T looks durable, Arvinas’ LRRK2 data, and more: Clinical Report

The week’s gainers and decliners after data readouts x
Read More
BioCentury | Nov 6, 2024
Product Development

Alzheimer’s roundup: Clinical progress and setbacks at CTAD

Readouts showcase promise of Roche’s brainshuttle; plus mixed results from Lilly, Lexeo and Anavex
Read More
BioCentury | Mar 15, 2024
Finance

Public equity report: PIPEs for Lexicon, Cybin, Regulus, Lexeo

Companies raise cash as they eye paths forward in diabetes, depression, kidney disease and Friedreich ataxia
Read More
BioCentury | Feb 7, 2024
Management Tracks

Verily names Myoung Cha as chief product officer

Plus: New CFO for Innovent and updates from Takeda, Shionogi, Lexeo, Stuart, Arcellx and more
Read More
BioCentury | Jan 12, 2024
Finance

The year of biotech’s recovery

Public Markets Preview: Investors say biotech outperformance in 2024 will hinge on the interest rate environment
Read More
BioCentury | Nov 10, 2023
Product Development

Nov. 10 Quick Takes: Cargo biggest biotech IPO to dip on first day

Plus: Madrigal identifies non-invasive efficacy assessment for NASH and updates from Novo and Valneva
Read More
BioCentury | Nov 7, 2023
Regulation

A DMD decision & endpoint innovation: a BioCentury podcast

Plus: FDA’s single trial guidance, the Promising Pathway Act and Lexeo’s NASDAQ debut
Read More
BioCentury | Nov 3, 2023
Finance

Lexeo cuts IPO price, becomes latest to lose value in first session

With gene therapy company’s dip Friday, seven of 10 major 2023 NASDAQ biotech listings have now traded down in the aftermarket since pricing
Read More
Items per page:
1 - 10 of 12